Step up versus early biologic therapy for Crohn's disease in clinical practice

Leyla J. Ghazi, Seema A. Patil, Ankur Rustgi, Mark H. Flasar, Sanam Razeghi, Raymond K. Cross

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Recent studies have demonstrated superior outcomes of early biologic therapy. Our purpose was to evaluate differences in disease course among patients in clinical practice treated with early biologic therapy compared with those receiving conventional Step Up therapy. Methods: Patients with Crohn's disease evaluated from July 2004 to November 2010 at a tertiary referral center were included. Demographic data were obtained from a prospectively maintained database. Patients were categorized into 1 of 2 groups: Early Bio group (with or without concomitant immune suppressants) or Step Up group (initial immune suppressants with or without escalation to biologic). Disease activity, quality of life, use of steroids, and number of hospitalizations, and surgeries were assessed. Results: Ninety-three patients with Crohn's disease met inclusion criteria: 39 (45%) in the Step Up group and 54 (58%) in the Early Bio group. There was no significant difference in demographic and clinical variables between groups. Mean Harvey-Bradshaw index and Short Inflammatory Bowel Disease Questionnaire scores at 3, 6, and 12 months were not different between groups. Response rates were higher in the Step Up group compared with the Early Bio group only at 3 months. Early Bio patients had a greater number of hospitalizations at 1 year (P = 0.04). Conclusions: In clinical practice, early biologic therapy did not improve disease activity or quality of life and did not decrease the need for steroids or surgeries 1 year after therapy. Our results suggest that clinical outcomes are not worsened using the conventional approach. Therefore, an accelerated Step Up approach for most patients seems reasonable.

Original languageEnglish (US)
Pages (from-to)1397-1403
Number of pages7
JournalInflammatory bowel diseases
Volume19
Issue number7
DOIs
StatePublished - Jun 1 2013

Fingerprint

Biological Therapy
Secondary Prevention
Crohn Disease
Hospitalization
Steroids
Quality of Life
Demography
Inflammatory Bowel Diseases
Tertiary Care Centers
Databases
Therapeutics

All Science Journal Classification (ASJC) codes

  • Gastroenterology
  • Immunology and Allergy

Cite this

Ghazi, Leyla J. ; Patil, Seema A. ; Rustgi, Ankur ; Flasar, Mark H. ; Razeghi, Sanam ; Cross, Raymond K. / Step up versus early biologic therapy for Crohn's disease in clinical practice. In: Inflammatory bowel diseases. 2013 ; Vol. 19, No. 7. pp. 1397-1403.
@article{584554bd96764ec89e674ce779a97fdd,
title = "Step up versus early biologic therapy for Crohn's disease in clinical practice",
abstract = "Background: Recent studies have demonstrated superior outcomes of early biologic therapy. Our purpose was to evaluate differences in disease course among patients in clinical practice treated with early biologic therapy compared with those receiving conventional Step Up therapy. Methods: Patients with Crohn's disease evaluated from July 2004 to November 2010 at a tertiary referral center were included. Demographic data were obtained from a prospectively maintained database. Patients were categorized into 1 of 2 groups: Early Bio group (with or without concomitant immune suppressants) or Step Up group (initial immune suppressants with or without escalation to biologic). Disease activity, quality of life, use of steroids, and number of hospitalizations, and surgeries were assessed. Results: Ninety-three patients with Crohn's disease met inclusion criteria: 39 (45{\%}) in the Step Up group and 54 (58{\%}) in the Early Bio group. There was no significant difference in demographic and clinical variables between groups. Mean Harvey-Bradshaw index and Short Inflammatory Bowel Disease Questionnaire scores at 3, 6, and 12 months were not different between groups. Response rates were higher in the Step Up group compared with the Early Bio group only at 3 months. Early Bio patients had a greater number of hospitalizations at 1 year (P = 0.04). Conclusions: In clinical practice, early biologic therapy did not improve disease activity or quality of life and did not decrease the need for steroids or surgeries 1 year after therapy. Our results suggest that clinical outcomes are not worsened using the conventional approach. Therefore, an accelerated Step Up approach for most patients seems reasonable.",
author = "Ghazi, {Leyla J.} and Patil, {Seema A.} and Ankur Rustgi and Flasar, {Mark H.} and Sanam Razeghi and Cross, {Raymond K.}",
year = "2013",
month = "6",
day = "1",
doi = "10.1097/MIB.0b013e318281337d",
language = "English (US)",
volume = "19",
pages = "1397--1403",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

Step up versus early biologic therapy for Crohn's disease in clinical practice. / Ghazi, Leyla J.; Patil, Seema A.; Rustgi, Ankur; Flasar, Mark H.; Razeghi, Sanam; Cross, Raymond K.

In: Inflammatory bowel diseases, Vol. 19, No. 7, 01.06.2013, p. 1397-1403.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Step up versus early biologic therapy for Crohn's disease in clinical practice

AU - Ghazi, Leyla J.

AU - Patil, Seema A.

AU - Rustgi, Ankur

AU - Flasar, Mark H.

AU - Razeghi, Sanam

AU - Cross, Raymond K.

PY - 2013/6/1

Y1 - 2013/6/1

N2 - Background: Recent studies have demonstrated superior outcomes of early biologic therapy. Our purpose was to evaluate differences in disease course among patients in clinical practice treated with early biologic therapy compared with those receiving conventional Step Up therapy. Methods: Patients with Crohn's disease evaluated from July 2004 to November 2010 at a tertiary referral center were included. Demographic data were obtained from a prospectively maintained database. Patients were categorized into 1 of 2 groups: Early Bio group (with or without concomitant immune suppressants) or Step Up group (initial immune suppressants with or without escalation to biologic). Disease activity, quality of life, use of steroids, and number of hospitalizations, and surgeries were assessed. Results: Ninety-three patients with Crohn's disease met inclusion criteria: 39 (45%) in the Step Up group and 54 (58%) in the Early Bio group. There was no significant difference in demographic and clinical variables between groups. Mean Harvey-Bradshaw index and Short Inflammatory Bowel Disease Questionnaire scores at 3, 6, and 12 months were not different between groups. Response rates were higher in the Step Up group compared with the Early Bio group only at 3 months. Early Bio patients had a greater number of hospitalizations at 1 year (P = 0.04). Conclusions: In clinical practice, early biologic therapy did not improve disease activity or quality of life and did not decrease the need for steroids or surgeries 1 year after therapy. Our results suggest that clinical outcomes are not worsened using the conventional approach. Therefore, an accelerated Step Up approach for most patients seems reasonable.

AB - Background: Recent studies have demonstrated superior outcomes of early biologic therapy. Our purpose was to evaluate differences in disease course among patients in clinical practice treated with early biologic therapy compared with those receiving conventional Step Up therapy. Methods: Patients with Crohn's disease evaluated from July 2004 to November 2010 at a tertiary referral center were included. Demographic data were obtained from a prospectively maintained database. Patients were categorized into 1 of 2 groups: Early Bio group (with or without concomitant immune suppressants) or Step Up group (initial immune suppressants with or without escalation to biologic). Disease activity, quality of life, use of steroids, and number of hospitalizations, and surgeries were assessed. Results: Ninety-three patients with Crohn's disease met inclusion criteria: 39 (45%) in the Step Up group and 54 (58%) in the Early Bio group. There was no significant difference in demographic and clinical variables between groups. Mean Harvey-Bradshaw index and Short Inflammatory Bowel Disease Questionnaire scores at 3, 6, and 12 months were not different between groups. Response rates were higher in the Step Up group compared with the Early Bio group only at 3 months. Early Bio patients had a greater number of hospitalizations at 1 year (P = 0.04). Conclusions: In clinical practice, early biologic therapy did not improve disease activity or quality of life and did not decrease the need for steroids or surgeries 1 year after therapy. Our results suggest that clinical outcomes are not worsened using the conventional approach. Therefore, an accelerated Step Up approach for most patients seems reasonable.

UR - http://www.scopus.com/inward/record.url?scp=84879094036&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879094036&partnerID=8YFLogxK

U2 - 10.1097/MIB.0b013e318281337d

DO - 10.1097/MIB.0b013e318281337d

M3 - Article

C2 - 23598813

AN - SCOPUS:84879094036

VL - 19

SP - 1397

EP - 1403

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 7

ER -